Palatin Technologies to move from NYSE American to Nasdaq in May May 18, 2026 04:00PM
Palatin to Begin Trading on Nasdaq Stock Exchange May 18, 2026 04:00PM
Palatin Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update May 13, 2026 07:30AM
Palatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update Feb 17, 2026 07:30AM
Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update Nov 13, 2025 07:30AM
View Older Stories

Nov 12, 2025 12:15PM Palatin Technologies closes $18.2 million public offering
Nov 12, 2025 12:15PM Palatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters' Over-Allotment Option
Nov 6, 2025 08:00AM Palatin Presents Data at ObesityWeek® 2025 Highlighting Promise of Melanocortin-Based Therapies for Obesity
Aug 8, 2025 04:00PM Palatin Technologies executes 1-for-50 reverse stock split
Aug 8, 2025 04:00PM Palatin Announces 1-for-50 Reverse Stock Split
May 14, 2025 07:30AM Palatin Reports Fiscal Year 2025 Third Quarter Results and Business Update
May 9, 2025 07:30AM Internet Patents (PTNT) vPresents Promising Preclinical Data on Melanocortin Agonists for Retinopathy
May 9, 2025 07:30AM Palatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025
May 8, 2025 10:19PM Palatin Technologies Announces Closing of Reduced Public Offering
May 8, 2025 04:39PM Palatin Presents Breakthrough Symptom Resolution Data from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease at ARVO 2025
May 7, 2025 08:01AM Palatin Technologies (PTN) Prices 76.67M Share Offering at $0.15/sh
May 7, 2025 08:00AM Palatin Technologies Announces Pricing of up to $23 Million Public Offering
May 5, 2025 07:30AM Palatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588 at ARVO 2025, Highlighting a Dual-Action Glaucoma Therapy
Apr 29, 2025 07:30AM Palatin Technologies (PTN) Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease
Apr 29, 2025 07:30AM Palatin Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease
Apr 17, 2025 07:30AM Palatin Technologies (PTN) Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide
Apr 17, 2025 07:30AM Palatin Reports Positive Appetite Suppression Results From Phase 2 Obesity Study of MC4R Agonist Bremelanotide and Tirzepatide
Apr 10, 2025 07:30AM Palatin Technologies (PTN) to Present Positive Phase 2b Data for Melanocortin Agonist
Apr 10, 2025 07:30AM Palatin to Present Positive Phase 2b Data for Melanocortin Agonist in Diabetic Kidney Disease at the National Kidney Foundation Spring Meeting
Mar 31, 2025 07:36AM Palatin Technologies (PTN) Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study
Mar 31, 2025 07:30AM Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study
Mar 28, 2025 07:30AM Palatin Technologies (PTN) Announces Positive Topline Results from Phase 2 Ulcerative Colitis Study of PL8177
Mar 28, 2025 07:30AM Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177
Mar 25, 2025 07:31AM Palatin Technologies' (PTN) PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency
Mar 25, 2025 07:30AM Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency
Feb 13, 2025 07:30AM Palatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Update
Feb 10, 2025 04:00PM Palatin to Report Second Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on February 13, 2025
Feb 7, 2025 08:00AM Palatin Technologies (PTN) Announces $4.7 Million Registered Direct Offering and Concurrent Private Placement
Feb 7, 2025 08:00AM Palatin Announces $4.7 Million Registered Direct Offering and Concurrent Private Placement
Feb 6, 2025 07:32AM Palatin Technologies (PTN) Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide
Feb 6, 2025 07:30AM Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide
Jan 28, 2025 07:31AM Palatin Technologies (PTN) Provides Update on Anticipated 2025 Corporate Milestones
Jan 28, 2025 07:30AM Palatin Provides Update on Anticipated 2025 Corporate Milestones
Dec 19, 2024 07:31AM Palatin Technologies (PTN) Announces Positive Phase IIb BREAKOUT Study Results
Dec 19, 2024 07:30AM Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy
Dec 16, 2024 07:31AM Palatin Technologies (PTN) Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds
Dec 16, 2024 07:30AM Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds
Nov 25, 2024 07:30AM Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis
Nov 14, 2024 07:30AM Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results
Nov 8, 2024 09:57AM Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024
Nov 4, 2024 07:30AM Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024
Oct 31, 2024 07:30AM Palatin Completes Enrollment in Phase 2 Clinical Study of Bremelanotide (MC4R Agonist) Co-Administered with Tirzepatide (GLP-1/GIP) for the Treatment of Obesity
Oct 24, 2024 07:30AM Inflammatory Disease Healing Data via Palatin's Novel Melanocortin Receptor Agonists Presented at the 19th Annual Peptide Therapeutics Symposium
Oct 23, 2024 07:30AM Palatin Presents Foundational Data on Novel and Highly Selective Melanocortin 4 Receptor Agonists at the 19th Annual Peptide Therapeutics Symposium
Oct 7, 2024 04:15PM Palatin Technologies (PTN) Receives NYSE Non-compliance Notice
Oct 7, 2024 04:15PM Palatin Receives Notice of Non-Compliance from NYSE American
Oct 1, 2024 07:30AM Palatin Reports Fourth Quarter and Fiscal Year Ended 2024 Financial Results, Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones
Sep 26, 2024 07:30AM Palatin to Report Fourth Quarter and Fiscal Year End 2024 Results
Sep 9, 2024 07:31AM Palatin Technologies (PTN) Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones
Sep 9, 2024 07:30AM Palatin Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones
View Older Stories